Skip to content
Screener

TG Therapeutics TGTX Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$192.6MBeat by $785.5K
EPS$0.14Miss by $0.21
Revenue estimate$191.8M
EPS estimate$0.35

Next report

Nov 2, 2026 (in a month)
Revenue estimate$245.2M
EPS estimate$0.36

Financials

Q4 2025

Income statement

See full
Revenue$192.6M+78.0%
Gross profit$154.4M+66.4%
Operating income$50.5M+68.6%
Net income$23.0M-1.3%
EPS (diluted)$0.150.0%

Balance sheet

See full
Cash & equivalents$79.1M-56.0%
Total debt$253.7M0.0%
Total equity$648.0M+191%
Total assets$1.1B+84.1%

Cash flow

See full
CapEx$67.0K+219%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$4.73B+1.0%
Enterprise value$4.91B+3.1%
P/E10.6×-190×
P/S7.7×-6.6×

Profitability

See full
Gross margin83.7%-4.6pp
Operating margin20%+7.3pp
Net margin72.6%+65.5pp

Returns & leverage

See full
Return on equity102.8%+90.5pp
Debt / equity0.4×-0.7×
Current ratio4.1×-2.1×

FAQ

When did TG Therapeutics report Q4 2025 earnings?
TG Therapeutics (TGTX) reported Q4 2025 earnings on February 26, 2026 before market open.
What were TG Therapeutics's Q4 2025 revenue and EPS?
TG Therapeutics reported revenue of $192.6M and eps of $0.14 for Q4 2025.
Did TG Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $191.8M by $785.5K. EPS missed the consensus estimate of $0.35 by $0.21.
How did TG Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 78.0% from $108.2M a year earlier and eps declined 6.7% from $0.15.
Where can I find TG Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001437749-26-005733) and the 10-K periodic report (0001437749-26-006133) directly on SEC EDGAR. The filing index links above go to sec.gov.